Display options
Cite
Bleyer A. Important factors improving outcome of young adults with acute lymphoblastic leukemia (ALL). Best Pract Res Clin Haematol. 2021;34(4):101322doi: 10.1016/j.beha.2021.101322.
Bleyer, A. (2021). Important factors improving outcome of young adults with acute lymphoblastic leukemia (ALL). Best practice & research. Clinical haematology, 34(4), 101322. https://doi.org/10.1016/j.beha.2021.101322
Bleyer, Archie. "Important factors improving outcome of young adults with acute lymphoblastic leukemia (ALL)." Best practice & research. Clinical haematology vol. 34,4 (2021): 101322. doi: https://doi.org/10.1016/j.beha.2021.101322
Bleyer A. Important factors improving outcome of young adults with acute lymphoblastic leukemia (ALL). Best Pract Res Clin Haematol. 2021 Dec;34(4):101322. doi: 10.1016/j.beha.2021.101322. Epub 2021 Oct 27. PMID: 34865694.
Copy Download .nbib Format: NLM
Share it on

Best Pract Res Clin Haematol. 2021 Dec;34(4):101322. doi: 10.1016/j.beha.2021.101322. Epub 2021 Oct 27.

Important factors improving outcome of young adults with acute lymphoblastic leukemia (ALL).

Best practice & research. Clinical haematology

Archie Bleyer

Affiliations

  1. Oregon Health and Science University, 2884 NW Horizon Dr. Bend, 97703, Portland, OR, USA; University of Texas McGovern Medical School, Houston, TX, USA. Electronic address: [email protected].

PMID: 34865694 DOI: 10.1016/j.beha.2021.101322

Abstract

Four categories of important factors improving outcome of young adults and older adolescents with acute lymphoblastic leukemia (ALL) are biologic type, clinical trials, pediatric vs. adult treatment regimen, and psychosocial challenges. Overall, the outcome of ALL in the age group has improved and beginning to catch up with that in children, as exemplified by CALGB 10403, a pediatric treatment regimen. Each is dependent for optimum development, however, on progress in the others. Without adequate psychosocial support and improvement, progress in clinical trials, translational research, and pediatric regimen application is impaired. Without clinical trials, advances in translational research, optimal pediatric regimen application and adequate psychosocial research are restricted. Overall, we have improved the outcome and outlook of ALL in AYAs, as exemplified by CALGB 10403, but we and our current and future patients still have a long way to go.

Copyright © 2021. Published by Elsevier Ltd.

Keywords: Acute lymphoblastic leukemia; Clinical trials; Incidence peak; Pediatric treatment regimen; Psychosocial care; Young adults

Publication Types